CRISPR Therapeutics AG
CRSP
Jodie situation report
CRISPR Therapeutics AG's current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 31 directly disclosed connections are confirming.
- CRSP's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CRSP's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind CRSP
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
VERXVertex, Inc.partnerMay 4, 2026 ▾
“CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex and certain of its affiliates.”
SIRISirius XM Holdings Inc.partnerMay 4, 2026 ▾
“We are also pursuing additional delivery technologies, including LNPs, for delivery to tissues beyond the liver, including hematopoietic stem cells and T cells.”
Depended on by
VRTXVertex Pharmaceuticals IncorporatedpartnerMay 5, 2026 ▾
“Over the last several years, we entered into collaboration agreements with a number of companies, including CRISPR T herapeutics AG (“CRISPR”) and Entrada Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 28 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CRSP is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.